Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
03/2011
03/09/2011EP2292631A1 Regeneration of endogenous myocardial tissue by induction of neovascularization
03/09/2011EP2292275A2 Protecting therapeutic compositions from host-mediated inactivation
03/09/2011EP2292274A1 Compositions and methods for protein production
03/09/2011EP2292250A1 Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline parvovirus and feline herpes virus
03/09/2011EP2291520A1 Nucleic acid molecule and method of targeting gene expression to gliomas
03/09/2011EP2291200A2 Methods for modulating expression of rbp4
03/09/2011EP1771570B1 Addition of transgenes into adenoviral vectors
03/09/2011EP1758999B1 METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA
03/09/2011EP1748069B1 Follistatin mutant polypeptide
03/09/2011EP1276887B1 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors
03/09/2011EP1181320B1 Somatic transgene immunization and related methods
03/09/2011CN101984056A RNA interference target RNA of long non-coding RNA related to human melanoma cells and application thereof
03/08/2011USRE42211 Relating to binding proteins for recognition of DNA
03/08/2011US7902441 Group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6 ,123F2 (RaSSFI), SEM A3 and Beta* (BLU), defined by homozygous deletion in lung cancer, have been located, isolated at 3p21.3
03/08/2011US7902348 Janus family kinases and identification of immune modulators
03/08/2011US7902165 Inhibiting of the proliferation of tumor cells is mediated by upregulation of the activity of p53
03/08/2011US7902164 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening
03/08/2011US7902160 ENA nucleic acid drugs modifying splicing in mRNA precursor
03/08/2011US7902151 Methods and compositions for modulating immunity
03/08/2011US7902149 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
03/08/2011US7901917 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis
03/08/2011US7901898 Tuberculosis diagnostic test
03/08/2011US7901706 Liposomes, micelles, polyelectrolytes; contact lenses; films; drug delivery; gene therapy
03/08/2011US7901693 Compositions and methods for WT1 specific immunotherapy
03/08/2011US7901683 Methods of inhibiting amyloid toxicity
03/08/2011US7901671 Therapeutic retroviral vectors for gene therapy
03/08/2011CA2498565C Composition for treating virus infection disease comprising jab1
03/08/2011CA2361251C Formulations comprising antisense nucleotides to connexins
03/08/2011CA2329054C A novel polypeptide hormone phosphatonin
03/08/2011CA2240516C Novel tyrosine kinase receptors and ligands
03/03/2011WO2011025862A2 Treatment of atp-binding cassette sub-family b member 1 (abcb1) related diseases by inhibition of natural antisense transcript to abcb1
03/03/2011WO2011025556A1 Targeting pax2 for the treatment of breast cancer
03/03/2011WO2011024918A1 Antiangiogenic agent and method for inhibition of angiogenesis
03/03/2011WO2011024480A1 Drug composition for angiogenesis therapy
03/03/2011WO2011024441A1 Ercc6l as target genes for cancer therapy and diagnosis
03/03/2011WO2011024428A1 Breast cancer related gene c12orf32
03/03/2011WO2010123648A3 Compositions and methods for the treatment of sepsis and other disorders involving phospholipase a2 induction
03/03/2011US20110055965 Cycle single-stranded nucleic acid complex and method for producing the same
03/03/2011US20110055940 Therapeutic Inhibitors of PAI-1 Function Methods of Their Use
03/03/2011US20110054160 Therapeutic compositions
03/03/2011US20110054159 Rna interference mediating small rna molecules
03/03/2011US20110054005 Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
03/03/2011US20110054003 Antisense oligonucleotide modulation of stat3 expression
03/03/2011US20110053863 Methods of using flt3-ligand in the treatment of cancer
03/03/2011US20110053860 COX-2 function and wound healing
03/03/2011US20110053781 Methods and compositions for polypeptide engineering
03/03/2011US20110053249 Adenoviruses Mutated In The VA Genes For Cancer Treatment
03/03/2011US20110053182 Diagnosis of pre-cancerous conditions using pcdgf agents
03/03/2011US20110052637 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as vaccines
03/03/2011US20110052632 Hiv polynucleotides and polypeptides derived from botswana mj4
03/03/2011US20110052628 Recombinant Double-Stranded RNA Phage, and Use of the Same
03/03/2011US20110052617 Aav scleroprotein, production and use thereof
03/03/2011US20110052615 Tumour-specific animal proteins
03/03/2011US20110052601 Compositions comprising anti-icam-1 antibodies
03/03/2011US20110052588 Method of treating hepatocellular carcinoma
03/03/2011US20110052584 Method of enhancement of cytotoxicity in antibody mediated immune responses
03/03/2011US20110052577 Antibodies
03/03/2011US20110052558 Materials and methods for prevention and treatment of rna viral diseases
03/03/2011US20110052540 Non-Aggregating Virus Formulation
03/03/2011CA2772036A1 Targeting pax2 for the treatment of breast cancer
03/02/2011EP2290104A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
03/02/2011EP2290103A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours
03/02/2011EP2290083A1 Conserved neisserial antigens
03/02/2011EP2290079A2 Neurotrophic factors
03/02/2011EP2290078A2 Immunostimulatory nucleic acids
03/02/2011EP2290054A1 Alphavirus particles and methods for preparation
03/02/2011EP2289910A2 Differential in tumour gene products and use of same
03/02/2011EP2289537A1 PDGF for use in the treatment of central nervous system disorders
03/02/2011EP2288387A1 Novel soluble cd83 polypeptides, formulations and methods of use
03/02/2011EP2288359A1 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
03/02/2011EP2288261A2 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
03/02/2011EP1740699B1 Connexin 40 tissue specific gene mutations
03/02/2011EP1436403B1 Use of the adenoviral e2 late promoter
03/02/2011EP1363663B1 Nucleic acid mucosal immunization
03/02/2011EP1185662B1 Dna vaccines for dogs
03/02/2011CN1832965B Endothelial cell specific antibodies and uses thereof
03/02/2011CN1748034B Improved expression element
03/02/2011CN1714150B Genetic products differentially expressed in tumors and the use thereof
03/02/2011CN1674935B Biofunctional composition containing CpG or oligo-/polynucleotide and toxin or enterotoxin
03/02/2011CN1646157B Multiple and multivalent DNA vaccines in ovo
03/01/2011US7897757 for treating, preventing, inhibiting, or reducing obesity, insulin resistance, diabetes and any other disease, trait, or condition that is related to or will respond to the levels of PTP-1B in a cell or tissue
03/01/2011US7897740 Secreted protein called 36P6D5 characteristic of tumors
03/01/2011US7897583 an antisense compound that hybridizes with a nucleic acid molecule that expreses PTPRU ( protein tyrosine phosphatase receptor type U), thereby inhibiting the expression of the nucleic acid molecule; treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia etc.
03/01/2011US7897581 Methods and compounds for promoting vessel regression
03/01/2011US7897562 Apoptosis-inducing agent and method for inducing apoptosis
03/01/2011US7897384 Chondrocyte therapeutic delivery system
03/01/2011US7897380 Circular nucleic acid vectors, and methods for making and using the same
03/01/2011US7897346 Polyamide nucleic acid derivatives and agents, and processes for preparing them
03/01/2011US7897158 Recombinant toxin fragments
03/01/2011US7897151 Anti-IgE vaccines
03/01/2011CA2677068A1 Nucleic acid compounds for inhibiting gene expression and uses thereof
03/01/2011CA2348954C A pharmaceutical composition for treating immune diseases
03/01/2011CA2339331C Expression and export of angiogenesis inhibitors as immunofusins
03/01/2011CA2323525C Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
02/2011
02/24/2011WO2011022606A2 Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
02/24/2011WO2011022427A1 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
02/24/2011WO2011021916A2 Use of egf-like domain of heregulin beta 1 peptide
02/24/2011WO2011021508A1 Marker for predicting therapeutic effect on hepatitis c, method for predicting therapeutic effect on hepatitis c, and prophylaxis or therapeutic agent for hepatitis c
02/24/2011WO2011020188A1 Peptide sequences and peptide-mediated sirna delivery
02/24/2011WO2010148065A9 Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1